首页
400-620-6333
sugemalimab
| 别名 | Cejemly® (China), CS-1001, WBP-3155, WBP3155, CS1001 |
|---|---|
| Compound Class | Antibody |
| 变动原因 |
Sugemalimab is a fully human, high-affinity anti-programmed death ligand 1 (PD-L1) IgG4 monoclonal antibody. It is a checkpoint inhibitor class immuno therapeutic. In vitro, it competitively blocks the binding of human PD-L1 to PD-1 and CD80, and it induces T lymphocyte proliferation and enhances antitumour immunity |
| Related Product | Sugemalimab (anti-PD-L1) |
Summary
| 是否批准为药物？ | |
|---|---|
| IUPAC Name | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 别名 | Cejemly® (China), CS-1001, WBP-3155, WBP3155, CS1001 |
数据库链接
| IMGT/mAb-DB | 1031 |
|---|
生物活性
| 生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
|---|
临床资料
| Summary of Clinical Use |
First-in-human safety, pharmacokinetics, preliminary efficacy for sugemalimab were reported in 2022 |
|---|---|
| 作用机制与药效学效应 |
Sulfonamides are structural analogues of 4-aminobenzoic acid (pABA) an intermediate in the de novo synthesis of folate by some prokaryotes, lower eukaryotes and plants |
参考文献
| 1. Gong J, Cao J, Zhang Q, Xu N, Zhao Y, Xing B, Miao Z, Wu Y, Pan H, Gao Q et al.. (2022) Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.. Cancer Immunol Immunother, 71 (8): (1897-1908). [PMID:34984540] |
| 2. Dhillon S, Duggan S. (2022) Sugemalimab: First Approval.. Drugs, 82 (5): (593-599). [PMID:35298827] |
危险品化学品经营许可证（带存储）